Enhanced HIV-1 neutralization by antibody heteroligation
about
Structural insights on the role of antibodies in HIV-1 vaccine and therapyResolve, revise, and relax: the 3 Rs of B cell repertoire adjustmentA gp41 MPER-specific Llama VHH Requires a Hydrophobic CDR3 for Neutralization but not for Antigen RecognitionA novel class of anti-HIV agents with multiple copies of enfuvirtide enhances inhibition of viral replication and cellular transmission in vitroNeutralization resistance of virological synapse-mediated HIV-1 Infection is regulated by the gp41 cytoplasmic tailRedemption of autoreactive B cells.Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen.Identification of autoantigens recognized by the 2F5 and 4E10 broadly neutralizing HIV-1 antibodiesIdentification and characterization of a broadly cross-reactive HIV-1 human monoclonal antibody that binds to both gp120 and gp41.Rapid conformational epitope mapping of anti-gp120 antibodies with a designed mutant panel displayed on yeastHIV takes double hit before entryEngineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.Polyreactivity and autoreactivity among HIV-1 antibodies.Cross-reactive broadly neutralizing antibodies: timing is everything.Antigen-driven induction of polyreactive IgM during intracellular bacterial infection.Effect of complement on HIV-2 plasma antiviral activity is intratype specific and potent.Delineation of autoantibody repertoire through differential proteogenomics in hepatitis C virus-induced cryoglobulinemia.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodiesCandidate antibody-based therapeutics against HIV-1.Improved outlook on HIV-1 prevention and vaccine development.Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies.How to assess the binding strength of antibodies elicited by vaccination against HIV and other viruses.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?Bispecific antibodies for viral immunotherapy.Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.HIV-Specific B Cell Frequency Correlates with Neutralization Breadth in Patients Naturally Controlling HIV-Infection.HIV-1 gp120 vaccine induces affinity maturation in both new and persistent antibody clonal lineages.Coupling of Single Molecule, Long Read Sequencing with IMGT/HighV-QUEST Analysis Expedites Identification of SIV gp140-Specific Antibodies from scFv Phage Display Libraries.Tandem bispecific neutralizing antibody eliminates HIV-1 infection in humanized mice.Conformational Plasticity in Broadly Neutralizing HIV-1 Antibodies Triggers Polyreactivity.
P2860
Q26829461-40820D76-8A58-487E-9E8F-1E1B3AE008EBQ26852927-5858A229-9C7F-4061-A7D3-CB1AB26A0280Q27676864-62BB1C93-5A05-42AB-AF64-9A6CA241D779Q28728917-3173A672-4DED-428F-ABF8-BE8AA1BFC609Q30524110-FD9CE6BC-692E-4AD5-A444-D6367BE9893AQ33835034-62C8AD11-262D-40FB-A005-A953A049EE8DQ33922778-43808157-A88F-4130-AC77-90BAAAAAA70AQ34324992-A8F8A009-FAAD-412F-BDAE-BC7DFF577E62Q34412302-AFCB5C81-311B-4E4C-8402-53C2610DA71EQ34480254-63DB5E42-9F22-4B73-B952-6B5BDA6935B3Q34502641-5DC8C229-3D43-4AB2-B635-E23F1D09AF29Q34531219-20D668AD-FF57-4D6E-9751-98592FDB0CA7Q34992787-3293E808-65BA-4FA8-BBE3-2D6E521B2BA9Q36105782-5FD8EEF0-4622-4928-B58C-1F53D91C30FFQ36106473-7034C9DB-7EE8-44C2-AE75-6C409FC1D68EQ36506821-6FCA738C-91C4-4B24-A5BF-E69D368D5720Q37086915-019A3B09-C5A7-492A-ADA7-89095BF9C4A7Q37621530-3EBEFBA4-31A7-44A9-B2AF-8BBFBA9BEA64Q37998496-950E6D7E-784E-4FF3-ABDD-02CB11B394DCQ38009870-1CA558E0-820A-43BD-B7AA-FB922604F327Q38038410-82B0F49B-9C56-47BD-8955-1F6139AFC29DQ38618790-4006F866-E6E4-4A57-B32A-BB3B5AA36513Q38717198-F9F3847F-177C-4A64-8C85-31D20DCC4C08Q38804059-9D573F54-7FFF-4963-AB82-BDD9684E8D6CQ38992408-B5C49917-0680-4A53-9FAF-ED6B22571461Q39261383-9A56568D-1DE7-43D6-B614-194AB27301CEQ40159913-F9581135-9CDD-4413-A205-666D9FCA91CDQ42270590-2FB30A1E-F9AD-4520-9132-FE5038A4F5BBQ52653118-A7A82111-FF1D-4030-AC63-BBA252BC752FQ52692811-FBC0DEF5-C14D-4EE6-93A7-25727335BD92Q55265892-7B8C25F6-D5A2-4D10-9DA5-8FB26907B79B
P2860
Enhanced HIV-1 neutralization by antibody heteroligation
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Enhanced HIV-1 neutralization by antibody heteroligation
@ast
Enhanced HIV-1 neutralization by antibody heteroligation
@en
type
label
Enhanced HIV-1 neutralization by antibody heteroligation
@ast
Enhanced HIV-1 neutralization by antibody heteroligation
@en
prefLabel
Enhanced HIV-1 neutralization by antibody heteroligation
@ast
Enhanced HIV-1 neutralization by antibody heteroligation
@en
P2093
P2860
P356
P1476
Enhanced HIV-1 neutralization by antibody heteroligation
@en
P2093
Hugo Mouquet
Johannes F Scheid
Malte Warncke
Michael S Seaman
P2860
P304
P356
10.1073/PNAS.1120059109
P407
P577
2012-01-04T00:00:00Z